Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.
|Title||Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.|
|Publication Type||Journal Article|
|Year of Publication||2015|
|Authors||Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T|
|Journal||J Alzheimers Dis|
|Keywords||Alzheimer Disease, Cholinergic Agents, Cognition, Double-Blind Method, Drug Therapy, Combination, Humans, Indans, Neuropsychological Tests, Nootropic Agents, Piperidines, Spiro Compounds, Treatment Outcome|
BACKGROUND AND OBJECTIVE: ST101, an acetylcholine release agent with efficacy in rodent memory and cognition models, was assessed for clinical safety and efficacy.METHODS: A phase 2 double blind, placebo-controlled study enrolled 210 AD patients (MMSE 10-20) on 10 mg donepezil QD. Patients received ST101 (10, 60, or 120 mg QD) or placebo for 12 weeks. The primary endpoint was change in cognitive function measured by ADAS-cog in the modified Intent To Treat (MITT) population and the Per Protocol (PP) population.RESULTS: Mean ADAS-cog change favored ST101 over placebo in the MITT population (p = 0.0957, one-sided) and in the PP population (p = 0.0434, one-sided, ∼1.5 point drug-placebo difference) comparing all ST101 dose groups combined to placebo. Among secondary and exploratory outcome measures the ADCS-CGIC also showed a beneficial trend (p = 0.0294, one-sided). In a post-hoc analysis, the subgroup with more severe disease (MMSE 10-17) showed a dose response in the ADAS-cog with the greatest efficacy at 120 mg (p = 0.0067, one sided). No significant ST101-related safety concerns were identified.CONCLUSION: The study supports the possibility that ST101, in patients receiving a stable dose of donepezil, may provide additional symptomatic benefit in moderate AD.
|Alternate Journal||J. Alzheimers Dis.|